Our Focus
The West Virginia Chapter of the National Bleeding Disorders Foundation, WVNBDF, provides education, support, awareness, and advocacy for the bleeding disorder community.
We are the leading resource for West Virginians affected by bleeding disorders. You can count on us to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Our Mission ... Into Action
-
We provide mission-focused experiences through education, support, community connections, and fun for those affected by bleeding disorders.
-
We provide year-round events and fundraisers to spread awareness, educate, and generate crucial resources in support of our mission. Hope to see you at our next event!
-
AdvocacyWe fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
News Articles
Bayer recently announced that the company’s hemophilia A therapy Jivi® has been granted an expanded indication from the U.S. Food and Drug Administration (FDA). Jivi is a long-acting site-specifically PEGylated recombinant factor VIII therapy that was first FDA-approved in 2018 for use in previously treated individuals with hemophilia A, including adolescents and adults 12 years of age and over. This indication encompassed prophylactic, on-demand, and perioperative management of bleeding.
Bayer recently announced that the company’s hemophilia A therapy Jivi® has been granted an expanded indication from the U.S. Food and Drug Administration (FDA). Jivi is a long-acting site-specifically PEGylated recombinant factor VIII therapy that was first FDA-approved in 2018 for use in previously treated individuals with hemophilia A, including adolescents and adults 12 years of age and over. This indication encompassed prophylactic, on-demand, and perioperative management of bleeding.
The New England Journal of Medicine (NEJM) recently published long-term follow up data on patients who have previously received the hemophilia B gene therapy fidanacogene elaparvovec. The therapy was approved by the U.S.
Advertisement
Click to learn more.
